{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:09:45Z","timestamp":1774616985007,"version":"3.50.1"},"reference-count":36,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Cardiovascular disease remains the number one cause of morbidity and mortality in the United States, despite major advances in our understanding of its pathogenesis and prevention. One reason for this continued epidemic is the poor adherence to treatment guidelines by caregivers and the lack of understanding by patients relative to its reversibility with treatment. Current guidelines are complex and often contradictory; there are at least 21 organizations publishing guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This article proposes a simplified approach that is based on the low-density lipoprotein (LDL) hypothesis stating that the lower the LDL cholesterol (LDL-C), the less the cardiovascular disease. This goal focuses on obtaining a plasma LDL-C &lt;50 mg\/dL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A positive coronary artery calcium scan in conjunction with an intermediate online cardiovascular risk score will identify individuals with substantial cardiovascular disease risk. With lifestyle improvements (including a low cholesterol diet) and low-dose hypolipemic generic oral medications, this LDL-C concentration is readily achievable in the majority of asymptomatic patients at risk for atherosclerosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Controlling the cardiovascular epidemic will require participation of both the patient and the physician caregiver. By simplifying the therapeutic regimen, patient compliance will increase, and an important reduction in cardiovascular morbidity and mortality will follow.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-02509","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T21:36:37Z","timestamp":1550698597000},"page":"6033-6039","source":"Crossref","is-referenced-by-count":14,"title":["A Simplified Approach to Reducing Cardiovascular Risk"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-604X","authenticated-orcid":false,"given":"David S","family":"Schade","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Philip","family":"Eaton","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"issue":"12","key":"2019102412391503300_bib1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"AHA statistical update: heart disease and stroke statistics\u20142018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"issue":"9753","key":"2019102412391503300_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2019102412391503300_bib3","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O\u2019Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2019102412391503300_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2261-14-60","article-title":"Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound","volume":"14","author":"Gao","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"issue":"18","key":"2019102412391503300_bib5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"9841","key":"2019102412391503300_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"2019102412391503300_bib7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.7326\/M16-1110","article-title":"Cardiovascular Risk Assessment: A Systematic Review of Guidelines","volume":"165","author":"Khanji","year":"2016","journal-title":"Ann Intern Med"},{"key":"2019102412391503300_bib8","author":"Grundy"},{"issue":"4","key":"2019102412391503300_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"2019102412391503300_bib10","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"issue":"9","key":"2019102412391503300_bib11","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","article-title":"Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis","volume":"3","author":"Sabatine","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"5","key":"2019102412391503300_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019102412391503300_bib13","author":"Travia"},{"key":"2019102412391503300_bib14","author":"Schade"},{"issue":"22","key":"2019102412391503300_bib15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2019102412391503300_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/FJC.0b013e318165dcad","article-title":"Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome","volume":"51","author":"Nakamura","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"issue":"15","key":"2019102412391503300_bib17","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jacc.2015.08.035","article-title":"10-Year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) Study and the DHS (Dallas Heart Study)","volume":"66","author":"McClelland","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2019102412391503300_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era","volume":"124","author":"Lazar","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"2019102412391503300_bib19","doi-asserted-by":"crossref","first-page":"e0116377","DOI":"10.1371\/journal.pone.0116377","article-title":"Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"10","author":"Roberts","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"2019102412391503300_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ahj.2009.08.007","article-title":"Cardiovascular events with absent or minimal coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"158","author":"Budoff","year":"2009","journal-title":"Am Heart J"},{"issue":"2","key":"2019102412391503300_bib21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.atherosclerosis.2014.07.022","article-title":"The effects of coronary artery calcium screening on behavioral modification, risk perception, and medication adherence among asymptomatic adults: a systematic review","volume":"236","author":"Mamudu","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"2019102412391503300_bib22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jacc.2009.08.088","article-title":"Determinants of coronary calcium conversion among patients with a normal coronary calcium scan: what is the \u201cwarranty period\u201d for remaining normal","volume":"55","author":"Min","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2019102412391503300_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcct.2017.02.010","article-title":"Clinical indications for coronary artery calcium scoring in asymptomatic patients: Expert consensus statement from the Society of Cardiovascular Computed Tomography","volume":"11","author":"Hecht","year":"2017","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2019102412391503300_bib24","author":"Thanassoulis"},{"issue":"4","key":"2019102412391503300_bib25","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.amjmed.2016.10.006","article-title":"Abnormal coronary artery calcium scans in asymptomatic patients","volume":"130","author":"Eaton","year":"2017","journal-title":"Am J Med"},{"issue":"15","key":"2019102412391503300_bib26","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jacc.2015.07.066","article-title":"Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology\/American Heart Association cholesterol management guidelines","volume":"66","author":"Nasir","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"2019102412391503300_bib27","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"2019102412391503300_bib28","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1210\/jc.2009-2689","article-title":"Approach to the patient who is intolerant of statin therapy","volume":"95","author":"Eckel","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019102412391503300_bib29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/M17-1566","article-title":"Statin denial: an internet-driven cult with deadly consequences","volume":"167","author":"Nissen","year":"2017","journal-title":"Ann Intern Med"},{"issue":"5","key":"2019102412391503300_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7326\/M13-1921","article-title":"N-of-1 (single-patient) trials for statin-related myalgia","volume":"160","author":"Joy","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019102412391503300_bib31","author":"Bacha"},{"issue":"9","key":"2019102412391503300_bib32","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1194\/jlr.M008144","article-title":"High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol","volume":"51","author":"Welder","year":"2010","journal-title":"J Lipid Res"},{"issue":"10","key":"2019102412391503300_bib33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0002-9149(02)02774-1","article-title":"Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia","volume":"90","author":"Gagn\u00e9","year":"2002","journal-title":"Am J Cardiol"},{"issue":"19","key":"2019102412391503300_bib34","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"2019102412391503300_bib35","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jacl.2018.06.001","article-title":"The effect of combined ezetimibe and statin therapy versus statin therapy alone on coronary plaque volume assessed by intravascular ultrasound: a systematic review and meta-analysis","volume":"12","author":"Mirzaee","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2019102412391503300_bib36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4236\/wjcd.2016.65012","article-title":"The application of the LDL principle","volume":"6","author":"Schade","year":"2016","journal-title":"World J Cardiovasc Dis"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/12\/6033\/30297591\/jc.2018-02509.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/12\/6033\/30297591\/jc.2018-02509.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T15:48:10Z","timestamp":1571932090000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/12\/6033\/5342943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-02509","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,2,20]]}}}